Want to see JP:3349 full AI Analyst Report?
Top Page
COSMOS Pharmaceutical Corporation
(3349)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥6,815.00
▲(3.07% Upside)
Action:Reiterated
Date:07/14/26
The score is driven primarily by solid fundamental stability (steady growth and a conservative balance sheet) offset by weak cash-flow conversion and mostly negative free cash flow. Technical indicators point to neutral-to-modestly positive near-term momentum but a weaker longer-term trend, while valuation is fair with a mid-teens P/E and a modest dividend yield.
Positive Factors
Steady revenue growth
Sustained top-line expansion demonstrates durable customer demand and successful store-level execution. A growing revenue base supports scale benefits in procurement and distribution, reducing per-unit costs and enabling reinvestment in stores and services over the medium term.
Negative Factors
Weak cash conversion
Low conversion of accounting profits to cash suggests working-capital absorption or non-cash income components, which constrains free cash available for dividends, buybacks, or debt reduction. Persistent weak conversion raises long-term funding and liquidity concerns.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Sustained top-line expansion demonstrates durable customer demand and successful store-level execution. A growing revenue base supports scale benefits in procurement and distribution, reducing per-unit costs and enabling reinvestment in stores and services over the medium term.
Read all positive factors
COSMOS Pharmaceutical Corporation (3349) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥547.65B
Dividend Yield1.28%
Average Volume (3M)399.89K
Price to Earnings (P/E)15.8
Beta (1Y)-0.22
Revenue Growth8.72%
EPS Growth3.45%
CountryJP
Employees5,709
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)404.32
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio4.18
Price to Book (P/B)1.63
Price to Sales (P/S)0.42
P/FCF Ratio-39.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥7,300.00Price Target Upside10.41% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)405.77
Revenue Forecast (FY)¥1.18T
COSMOS Pharmaceutical Corporation Business Overview & Revenue Model
Company Description
COSMOS Pharmaceutical Corporation (3349) is a Japan-based company in the healthcare/consumer pharmaceuticals space. It operates a drugstore retail business under the "Cosmos" brand, selling prescription drugs (through in-store pharmacies where app...
How the Company Makes Money
COSMOS Pharmaceutical primarily makes money through retail sales at its Cosmos drugstores. Its core revenue streams are (1) sales of pharmaceuticals and health-related products (including OTC medicines and other health/beauty items) and (2) sales ...
COSMOS Pharmaceutical Corporation Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.10T | 1.01T | 964.99B | 827.70B | 755.41B |
| Gross Profit | 229.68B | 213.28B | 188.31B | 168.72B | 151.45B |
| EBITDA | 66.93B | 64.85B | 53.74B | 50.19B | 48.21B |
| Net Income | 32.05B | 30.98B | 24.45B | 23.80B | 23.16B |
Balance Sheet | |||||
| Total Assets | 596.49B | 525.17B | 476.98B | 421.41B | 363.50B |
| Cash, Cash Equivalents and Short-Term Investments | 61.34B | 57.04B | 52.30B | 45.93B | 37.36B |
| Total Debt | 78.48B | 49.96B | 34.06B | 18.20B | 9.41B |
| Total Liabilities | 312.78B | 267.71B | 245.53B | 210.33B | 172.99B |
| Stockholders Equity | 283.70B | 257.46B | 231.44B | 211.07B | 190.51B |
Cash Flow | |||||
| Free Cash Flow | -11.67B | -859.00M | -859.00M | -635.00M | 7.80B |
| Operating Cash Flow | 58.79B | 52.47B | 52.47B | 55.17B | 54.43B |
| Investing Cash Flow | -81.90B | -55.45B | -55.45B | -57.33B | -49.11B |
| Financing Cash Flow | 19.32B | 7.72B | 7.72B | 8.53B | 3.25B |
COSMOS Pharmaceutical Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥220.95B | 12.66 | ― | 2.35% | 8.76% | 8.19% | |
68 Neutral | ¥457.52B | 14.09 | 11.29% | 3.42% | 5.08% | 2.07% | |
67 Neutral | ¥574.86B | 16.66 | 10.75% | 1.20% | 12.20% | -25.42% | |
64 Neutral | ¥547.65B | 15.79 | ― | 1.28% | 8.72% | 3.45% | |
62 Neutral | ¥1.15T | 18.84 | 7.67% | 2.04% | ― | ― | |
54 Neutral | ¥401.01B | 22.68 | ― | 0.41% | 13.04% | 0.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:3349
COSMOS Pharmaceutical Corporation
6,383.00
-3,067.28
-32.46%
JP:9989
Sundrug Co
3,780.00
-665.12
-14.96%
JP:7649
Sugi Holdings Co
2,822.50
-881.06
-23.79%
JP:3391
TSURUHA Holdings
2,424.00
211.26
9.55%
JP:3148
Create SD Holdings Co., Ltd.
3,330.00
-89.39
-2.61%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,020.00
-40.36
-0.99%
COSMOS Pharmaceutical Corporation Corporate Events
COSMOS Pharmaceutical Raises Year-End Dividend, Lifts Annual Payout
Jul 13, 2026
COSMOS Pharmaceutical Corporation’s board has approved a year-end dividend of 44.50 yen per share for the fiscal year ended May 31, 2026, up from 37.50 yen a year earlier. The total payout will be 3,526 million yen, with the dividend schedul...
COSMOS Pharmaceutical Lifts Sales and Dividends but Flags Profit Dip Ahead
Jul 13, 2026
COSMOS Pharmaceutical posted an 8.7% rise in net sales to ¥1.10 trillion for the fiscal year ended May 31, 2026, while profit attributable to owners of the parent edged up 3.4% to ¥32.0 billion. Margins softened slightly as operating pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.